The early therapeutics BsAbs were T cell engagers, and their effects were first demonstrated in the mid-1980s.104,105 BiTEs are capable of binding CD3ε within the TCR complex and a selected tumor-associated antigen (TAA) on tumor cells simultaneously. This evidence concerns the gene CD3E and neoplasm.